Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Cancer × CS-1003 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Solid Tumor, Adult 1 Carcinoma, Hepatocellular 1 Advanced Cancer 1

Interventions

Nivolumab 14 Ipilimumab 6 linrodostat 5 relatlimab 3 Pemetrexed 3 Paclitaxel 3 Docetaxel 3 Carboplatin 3 ARRY-334543 3 regorafenib 2 abemaciclib 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Gemcitabine 2 Capecitabine 2 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 vorolanib 1 trametinib 1 tislelizumab 1 sargramostim 1 ralimetinib 1 prexasertib 1 palifosfamide lysine 1 p38 Mitogen-Activated Protein Kinases 1 lirilumab 1 fluzoparib 1 fluorapacin 1 figitumumab 1 etirinotecan pegol 1 emibetuzumab 1 efatutazone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03475251 2022-02-18

A Study of CS1003 in Subjects With Advanced Solid Tumors

CStone Pharmaceuticals

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡